Celltrion, Inc. Stock price

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. 07:00:00 2024-03-17 pm EDT 5-day change 1st Jan Change
182,500 KRW +0.94% Intraday chart for Celltrion, Inc. +1.67% -9.43%
Sales 2023 2,176B 1.63B Sales 2024 * 3,474B 2.59B Capitalization 37,828B 28.26B
Net income 2023 536B 400M Net income 2024 * 656B 490M EV / Sales 2023 12.9 x
Net cash position 2023 * 97.38B 72.74M Net Debt 2024 * 1,628B 1.22B EV / Sales 2024 * 11.4 x
P/E ratio 2023 *
37.6 x
P/E ratio 2024 *
56.8 x
Employees 2,034
Yield 2023 *
0.2%
Yield 2024 *
0.2%
Free-Float 36.53%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.94%
1 week+1.67%
Current month+1.56%
1 month+0.16%
3 months+2.99%
6 months+24.66%
Current year-9.43%
More quotes
1 week
177 700.00
Extreme 177700
184 400.00
1 month
172 300.00
Extreme 172300
193 400.00
Current year
172 300.00
Extreme 172300
241 000.00
1 year
131 000.00
Extreme 131000
241 000.00
3 years
131 000.00
Extreme 131000
315 328.05
5 years
121 026.29
Extreme 121026.2888
372 915.00
10 years
27 751.54
Extreme 27751.5426
372 915.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 07-04-23
Director of Finance/CFO 49 -
Chairman 66 -
Members of the board TitleAgeSince
Director/Board Member 73 -
Chairman 66 -
Director/Board Member 71 14-12-07
More insiders
Date Price Change Volume
24-03-18 182,500 +0.94% 534,945
24-03-15 180,800 +0.78% 1,046,380
24-03-14 179,400 +0.34% 1,833,620
24-03-13 178,800 -1.60% 457,993
24-03-12 181,700 +1.23% 422,573

End-of-day quote Korea S.E., March 17, 2024

More quotes
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical Pharmaceutical segment is involved in the manufacturing and sale of therapeutic drugs for liver disease under the name of Godex, as well as the treatment of autoimmune diseases under the name of Remsima. The Other segment manufactures and sells other generic drugs. The Company distributes its products within the domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
182,500 KRW
Average target price
221,118 KRW
Spread / Average Target
+21.16%
Consensus
  1. Stock
  2. Equities
  3. Stock Celltrion, Inc. - Korea S.E.